

February 01, 2024

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company held on February 01, 2024

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has at its meeting held on Thursday, February 01, 2024, *inter-alia* Considered and approved:

1. Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2023. The said Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Re-appointment of and payment of remuneration to Mr. Yugal Sikri (DIN: 07576560) as Managing Director of the Company for a term of 1 (one) year effective from May 1, 2024 to April 30, 2025, subject to approval of the shareholders. Details required as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1 /P/CI R/2023/123 dated July 13, 2023 are enclosed as **Annexure - A**.
3. Postal ballot notice for seeking approval of shareholders through special resolutions with respect to the following:
 - a) Re-appointment of and payment of remuneration to Mr. Yugal Sikri as Managing Director of the Company for a term of 1 (one) year effective from May 1, 2024 to April 30, 2025.
 - b) Revision in special performance incentive payable to Mr. Yugal Sikri (DIN: 07576560), Managing Director.

The meeting commenced at 02:00 p.m. and concluded at 05.30 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,

For RPG Life Sciences Limited

RAJESH RAMESH SHIRAMBEKAR
Digitally signed by RAJESH RAMESH SHIRAMBEKAR
Date: 2024.02.01 17:34:18 +05'30'

Rajesh Shirambekar
Head – Legal & Company Secretary





Annexure – A

(Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Pursuant to recommendation of the Nomination and Remuneration Committee and the Board of Directors, Mr. Yugal Sikri (DIN: 07576560) is re-appointed as Managing Director of the Company effective from May 1, 2024 to April 30, 2025, subject to approval of shareholders.
2	Date of re-appointment	May 1, 2024
	Term of re-appointment	1 (one) year from May 1, 2024 to April 30, 2025 (both days inclusive)
3	Brief Profile (in case of appointment)	<p>Mr. Sikri is a senior pharma industry professional with rich and diverse experience in pharmaceutical industry. Mr. Sikri is responsible for the overall conduct and management of business and affairs of the Company. This includes broad development of domestic and international business; providing strategic direction to the three business units of the Company; review of product portfolio in light of patent laws and continual introduction of new products; enhancement of manufacturing efficiencies and rationalization of costs.</p> <p>Mr. Sikri has successfully handled and overlooked domestic and international business for reputed companies like GlaxoSmithKline, Warner Lambert/ Pfizer, Novartis, Ranbaxy and RPGLS for many years. He is also an Independent Director on the Board of AIC NMIMS Incubation Centre.</p> <p>Mr. Sikri was honoured with 'Outstanding Achiever Award 2020' award by the RPG Group.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Yugal Sikri is not related to any Director or Key Managerial Personnel of the Company.
5	Affirmation	Based on the information available with the Company, Mr. Yugal Sikri is not debarred from holding the office of a director by virtue of any SEBI order or any other such authority.



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited (the "Company") for the quarter ended December 31, 2023 and year to date from April 01, 2023, to December 31, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003


per Aruna Kumaraswamy
Partner
Membership No.: 219350
UDIN: 24219350BK15TM5102



Place: Mumbai
Date: February 01, 2024

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

Particulars	(Rs. in Lakhs)					
	Quarter ended			Nine months ended		Year ended
	31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023
Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 Revenue from Operations	15,370	15,358	13,060	45,506	39,432	51,281
2 Other Income	192	183	51	556	296	480
3 Total Income (1+2)	15,562	15,541	13,111	46,062	39,728	51,761
4 Expenses						
(a) Cost of Materials Consumed	2,485	3,730	2,026	9,262	6,370	8,612
(b) Purchases of Stock-in-Trade	1,649	1,311	2,539	4,626	7,179	9,205
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	683	(567)	(318)	421	(411)	(730)
(d) Employee Benefits Expense	3,369	3,359	2,829	10,007	8,329	11,706
(e) Finance Costs	14	10	7	31	26	31
(f) Depreciation and Amortisation Expense	414	423	391	1,258	1,161	1,550
(g) Other Expenses	3,394	3,796	3,063	10,447	9,287	12,219
Total Expenses	12,008	12,062	10,537	36,052	31,941	42,593
5 Profit before tax (3-4)	3,554	3,479	2,574	10,010	7,787	9,168
6 Income tax expenses						
a. Current Tax	950	967	692	2,709	2,066	2,435
b. Deferred Tax	(42)	(74)	(29)	(141)	(8)	(31)
Total tax expenses	908	893	663	2,568	2,058	2,404
7 Profit for the period (5-6)	2,646	2,586	1,911	7,442	5,729	6,764
8 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	2	3	(9)	7	(27)	9
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(1)	(1)	3	(3)	7	(2)
Other Comprehensive Income Net of Tax	1	2	(6)	4	(20)	7
9 Total Comprehensive Income for the period (7+8)	2,647	2,588	1,905	7,446	5,709	6,771
10 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
11 Other Equity						29,437
12 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
(a) Basic (in Rs.)	16.00	15.64	11.56	45.00	34.64	40.90
(b) Diluted (in Rs.)	16.00	15.64	11.56	45.00	34.64	40.90

Notes:

- The above Unaudited Financial Results have been reviewed and recommended by the Audit Committee at its meeting held on January 31, 2024 and have been approved by the Board of Directors at its meeting held on February 01, 2024.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- Previous period's figures have been regrouped/reclassified wherever necessary.



For RPG Life Sciences Limited

Yugal Sikri

Yugal Sikri
 DIN: 07576560
 Managing Director
 Mumbai, February 01, 2024

B.M. D